Article
Health Care Sciences & Services
Bogdan Marian Caraban, Elena Matei, Georgeta Camelia Cozaru, Mariana Aschie, Mariana Deacu, Manuela Enciu, Gabriela Izabela Baltatescu, Anca Chisoi, Nicolae Dobrin, Lucian Petcu, Emma Gheorghe, Laurentiu-Tony Hangan, Mihai Catalin Rosu, Cristian Ionut Orasanu, Antonela-Anca Nicolau
Summary: This study aimed to characterize the PD-L1 expression in melanomas and its association with T cell infiltrates. The results showed that most of the PD-L1 positive tumors had moderate scores of CD4+ and CD8+ TILs in tumoral melanoma cells. PD-L1 expression was associated with different degrees of lymphocytic infiltration and with Breslow tumor thickness. PD-L1 expression is a predictive biomarker for discriminating the presence or absence of malign tumoral melanoma cells and an independent predictor of good prognosis in melanoma patients.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Yifan Zhang, Yi Chen, Andri Papakonstantinou, Panagiotis Tsagkozis, Christina Linder-Stragliotto, Felix Haglund
Summary: This study investigated the PD-L1 immunoreactivity in high-grade chondrosarcomas, abdominal liposarcoma, and undifferentiated pleomorphic sarcomas. It found that the majority of tumors exhibited low PD-L1 immunoreactivity, but a subset showed high immunoreactivity. However, there was no significant difference in metastasis-free or overall survival in relation to PD-L1 immunoreactivity in any subtype.
Article
Biochemistry & Molecular Biology
Paloma Lequerica-Fernandez, Julian Suarez-Canto, Tania Rodriguez-Santamarta, Juan Pablo Rodrigo, Faustino Julian Suarez-Sanchez, Veronica Blanco-Lorenzo, Francisco Dominguez-Iglesias, Juana Maria Garcia-Pedrero, Juan Carlos de Vicente
Summary: This study found that TILs in OSCC patients were associated with PD-L1 expression and CSC markers. CD4(+) and CD8(+) TILs were related to smoking and alcohol habits. High infiltration of CD4(+) and CD8(+) TILs was significantly associated with tumors harboring positive PD-L1 expression.
Article
Biochemistry & Molecular Biology
Rocio Garcia-Marin, Sara Reda, Cristina Riobello, Virginia N. Cabal, Laura Suarez-Fernandez, Blanca Vivanco, Cesar Alvarez-Marcos, Fernando Lopez, Jose L. Llorente, Mario A. Hermsen
Summary: Sinonasal squamous cell carcinoma (SNSCC) is an aggressive tumor with a poor prognosis. Immunotherapy may be a new therapeutic option for SNSCC patients, especially for the subgroup with high CD8(+) TILs and PD-L1 positivity.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Immunology
Zhiheng Wu, Yu Zheng, Jin Sheng, Yicheng Han, Yanyan Yang, Hongming Pan, Junlin Yao
Summary: This article comprehensively reviews the origin, distribution, and functions of DN T cells, focusing on their roles in inflammation, immune disorders, and cancer. It also discusses the recent advances in DN T cell-based therapy for cancer treatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Xiangfei Sun, Ping Shu, Yong Fang, Wei Yuan, Qiang Zhang, Jianyi Sun, Min Fu, Anwei Xue, Xiaodong Gao, Kuntang Shen, Yingyong Hou, Yihong Sun, Jing Qin, Xinyu Qin
Summary: The study found that PD-L1 expression is a predictive biomarker for better prognosis of GISTs. Non-gastric GIST patients, especially those with wild-type mutations, may benefit from PD-1/PD-L1 inhibitors.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Romain Banchereau, Avantika S. Chitre, Alexis Scherl, Thomas D. Wu, Namrata S. Patil, Patricia de Almeida, Edward E. Kadel, Shravan Madireddi, Amelia Au-Yeung, Chikara Takahashi, Ying-Jiun Chen, Zora Modrusan, Jacqueline McBride, Rhea Nersesian, Ehab A. El-Gabry, Mark D. Robida, Jeffrey C. Hung, Marcin Kowanetz, Wei Zou, Mark McCleland, Patrick Caplazi, Shadi Toghi Eshgi, Hartmut Koeppen, Priti S. Hegde, Ira Mellman, W. Rodney Mathews, Thomas Powles, Sanjeev Mariathasan, Jane Grogan, William E. O'Gorman
Summary: CD8+ tissue-resident memory T (T-RM) cells expressing CD103 (ITGAE) are believed to actively suppress cancer progression, and their presence in tumors may predict response to immunotherapy. This study found that in inflamed tumors, CD103+ CD8+ T-RM cells exhibit a complex phenotype characterized by increased clonal expansion, expression of checkpoint regulators, and cytotoxic proteins, suggesting their involvement in antitumor response.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Editorial Material
Oncology
Werner Held, Daniel E. Speiser
Summary: Adoptive cell immunotherapy using in vitro expanded autologous tumor-infiltrating lymphocytes shows potential for durable remission in certain cancers, but complete and long-lasting control of metastatic melanoma requires tumor-specific CD8(+) T cells with stem-cell-like properties.
Article
Oncology
Julie Niogret, Helene Berger, Cedric Rebe, Romain Mary, Elise Ballot, Caroline Truntzer, Marion Thibaudin, Valentin Derangere, Christophe Hibos, Lea Hampe, David Rageot, Theo Accogli, Philippe Joubert, Bertrand Routy, James Harker, Frederique Vegran, Francois Ghiringhelli, Fanny Chalmin
Summary: Tfh cells play an important role in antitumor immune response, especially in a CD8(+)-dependent manner, by producing interleukin-21 to support the function of exhausted T cells. Their accumulation in tumor sites and draining lymph nodes is closely associated with treatment efficacy and patient survival.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Yu-meng Wang, Jun-jun Qiu, Xin-yu Qu, Jing Peng, Chong Lu, Meng Zhang, Ming-Xing Zhang, Xing-ling Qi, Bin Lv, Jing-Jing Guo, Chen-yan Guo, Gui-ling Li, Ke-qin Hua
Summary: This study identified a population of PD-1+ DCs in the tumor microenvironment of cervical cancer. PD-1+ DCs were associated with advanced stages of cancer and functional impairments in immune response. Blockade of PD-1 reinvigorated PD-1+ DCs and enhanced the therapeutic effect of PD-1 blockade treatment. The density of PD-1+ DCs in the tumor microenvironment may serve as a diagnostic factor for predicting the optimal beneficiaries of PD-1/PD-L1 blockade immunotherapy in cervical cancer.
Article
Cell Biology
Mariana O. Diniz, Anna Schurich, Senthil K. Chinnakannan, Marion Duriez, Kerstin A. Stegmann, Jessica Davies, Stephanie Kucykowicz, Kornelija Suveizdyte, Oliver E. Amin, Frances Alcock, Tamsin Cargill, Eleanor Barnes, Mala K. Maini
Summary: This study demonstrates that NK cell depletion enhances the immune response to vaccines in a mouse model of chronic HBV infection. It was found that the up-regulation of PD-L1 on liver-resident NK cells and PD-1 on intrahepatic T cells plays a negative regulatory role in the response to therapeutic vaccination. Combining cytokine activation with PD-L1 blockade can convert NK cells into efficient helpers, boosting the CD8(+) T cell response to therapeutic vaccination.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Article
Oncology
Lata Singh, Mithalesh Kumar Singh, Maria Cristina Kenney, Martine J. Jager, Moshahid Alam Rizvi, Rachna Meel, Neiwete Lomi, Sameer Bakhshi, Seema Sen, Seema Kashyap
Summary: The study showed that the expression of PD-1 and PD-L1 in UM is related to TILs presence and patient prognosis. TILs promote the expression of PD-1 and PD-L1, impacting the DFS rate. Treatment of UM cells with IFN-gamma induced PD-1 expression, while also leading to increased PD-L1 expression.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Review
Pharmacology & Pharmacy
Sandeep Kumar, Sunil Kumar Singh, Basabi Rana, Ajay Rana
Summary: The crucial role of host immunity in clinical cancer management is highlighted, emphasizing the importance of therapies that can enhance tumor cell death and bolster host immunity. The impact of the tumor microenvironment on CD8+ T cell exhaustion and survival is discussed, along with potential strategies for restoring CD8+ T cell effector function through immunotherapy.
DRUG DISCOVERY TODAY
(2021)
Article
Chemistry, Medicinal
Chengliang Sun, Mingxiao Yin, Yao Cheng, Zean Kuang, Xiaojia Liu, Gefei Wang, Xiao Wang, Kai Yuan, Wenjian Min, Jingwen Dong, Yi Hou, Lingrong Hu, Guoyu Zhang, Wenli Pei, Liping Wang, Yanze Sun, Xinmiao Yu, Yibei Xiao, Hongbin Deng, Peng Yang
Summary: S4-1 is an innovative small-molecule inhibitor of PD-L1 that effectively alters the PD-L1/PD-1 interaction, enhances cytotoxicity of immune cells towards tumor cells, and shows significant tumor growth inhibition in vivo. It also activates T-cells and reverses the inhibitory tumor microenvironment.
JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Immunology
Rui Yang, Susu Shen, Cheng Gong, Xin Wang, Fang Luo, Fengyan Luo, Yang Lei, Zili Wang, Shasha Xu, Qian Ni, Yan Xue, Zhen Fu, Liang Zeng, Lijuan Fang, Yongxiang Yan, Jing Zhang, Lu Gan, Jizu Yi, Pengfei Zhou
Summary: The study demonstrated that the bispecific antibody Y111 efficiently bridged T cells and PD-L1 expressing tumor cells, which enhanced the cytotoxicity of expanded V gamma 2V delta 2 T cells against PD-L1 positive tumor cells. The combination of expanded V gamma 2V delta 2 T cells with Y111 could potentially offer a novel approach for immunotherapy in treating PD-L1 positive solid tumors.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Arpit Chhabra, Leonard T. Ong, Deborah Kuk, Geoffrey Ku, David Ilson, Yelena Y. Janjigian, Abraham Wu, Heiko Schoeder, Karyn A. Goodman
BRITISH JOURNAL OF CANCER
(2015)
Article
Oncology
Brian H. Kushner, Stephen S. Roberts, Danielle N. Friedman, Deborah Kuk, Irina Ostrovnaya, Shakeel Modak, Kim Kramer, Ellen M. Basu, Nai-Kong V. Cheung
Article
Oncology
Mrinal Gounder, Ved Desai, Deborah Kuk, Narasimhan Agaram, Maria Arcila, Benjamin Durham, Mary L. Keohan, Mark A. Dickson, Sandra P. D'Angelo, Neerav Shukla, Craig Moskowitz, Ariela Noy, Robert G. Maki, Diego Adrianzen Herrera, Armando Sanchez, Anita Krishnan, Andrew Pourmoussa, Li-Xuan Qin, William D. Tap
EUROPEAN JOURNAL OF CANCER
(2015)
Article
Oncology
Aimee M. Crago, Juliann Chmielecki, Mara Rosenberg, Rachael O'Connor, Caitlin Byrne, Fatima G. Wilder, Katherine Thorn, Phaedra Agius, Deborah Kuk, Nicholas D. Socci, Li-Xuan Qin, Matthew Meyerson, Meera Hameed, Samuel Singer
GENES CHROMOSOMES & CANCER
(2015)
Article
Oncology
Narasimhan P. Agaram, Lei Zhang, Francois LeLoarer, Tarik Silk, Yun-Shao Sung, Sasinya N. Scott, Deborah Kuk, Li-Xuan Qin, Michael F. Berger, Cristina R. Antonescu, Samuel Singer
GENES CHROMOSOMES & CANCER
(2016)
Article
Oncology
Rita E. Morales, Alexander N. Shoushtari, Michelle M. Walsh, Priya Grewal, Evan J. Lipson, Richard D. Carvajal
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2015)
Article
Oncology
Sandra P. D'Angelo, Shailender Bhatia, Andrew S. Brohl, Omid Hamid, Janice M. Mehnert, Patrick Terheyden, Kent C. Shih, Isaac Brownell, Celeste Lebbe, Karl D. Lewis, Gerald P. Linette, Michele Milella, Sara Georges, Parantu Shah, Barbara Ellers-Lenz, Marcis Bajars, Guelseren Guezel, Paul T. Nghiem
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2020)
Article
Oncology
Sandra P. D'Angelo, Celeste Lebbe, Laurent Mortier, Andrew S. Brohl, Nicola Fazio, Jean-Jacques Grob, Natalie Prinzi, Glenn J. Hanna, Jessica C. Hassel, Felix Kiecker, Sara Georges, Barbara Ellers-Lenz, Parantu Shah, Gulseren Guezel, Paul Nghiem
Summary: In patients with mMCC, first-line treatment with avelumab led to responses in 40% and durable responses in 30%, being associated with a low rate of grade 3/4 treatment-related adverse events.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Ping Chi, Li-Xuan Qin, Bastien Nguyen, Ciara M. Kelly, Sandra P. D'Angelo, Mark A. Dickson, Mrinal M. Gounder, Mary L. Keohan, Sujana Movva, Benjamin A. Nacev, Evan Rosenbaum, Katherine A. Thornton, Aimee M. Crago, Sam Yoon, Gary Ulaner, Randy Yeh, Moriah Martindale, Haley T. Phelan, Matthew D. Biniakewitz, Sarah Warda, Cindy J. Lee, Michael F. Berger, Nikolaus D. Schultz, Samuel Singer, Sinchun Hwang, Yu Chen, Cristina R. Antonescu, William D. Tap
Summary: This study demonstrates that the combination of imatinib and binimetinib shows efficacy and manageable toxicity in the first-line treatment of GIST.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Juliane Manitz, Sandra P. D'Angelo, Andrea B. Apolo, S. Peter Eggleton, Marcis Bajars, Oliver Bohnsack, James L. Gulley
Summary: This study compared tumor responses evaluated by RECIST 1.1 and immune-related RECIST (irRECIST) in patients with different types of tumors treated with avelumab. The correlation between progression-free survival (PFS) and overall survival (OS) was also evaluated. The results showed that irRECIST could identify a subset of patients classified as progressive disease (PD) by RECIST 1.1 but with immune-related disease control by irRECIST, providing clinically relevant information. However, as a surrogate endpoint for OS in the whole population, immune-related PFS did not show improved predictive value compared with PFS by RECIST 1.1.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Lukas Kraehenbuehl, Aliya Holland, Emma Armstrong, Sirinya O'Shea, Levi Mangarin, Sara Chekalil, Amanda Johnston, John S. Bomalaski, Joseph P. Erinjeri, Christopher A. Barker, Jasmine H. Francis, Jedd D. Wolchok, Taha Merghoub, Alexander N. Shoushtari
Summary: Uveal melanoma is a rare and highly malignant subtype of melanoma, often leading to metastasis, with the liver being the most commonly affected organ. Unlike cutaneous melanoma, uveal melanoma has a poor response to immune checkpoint blockade treatment. The investigation of a new combination therapy consisting of immunotherapy medications and a metabolic therapy did not show significant improvement in the treatment outcome beyond the limited efficacy of approved immunotherapy alone.
Article
Multidisciplinary Sciences
Sandra P. D'Angelo, Allison L. Richards, Anthony P. Conley, Hyung Jun Woo, Mark A. Dickson, Mrinal Gounder, Ciara Kelly, Mary Louise Keohan, Sujana Movva, Katherine Thornton, Evan Rosenbaum, Ping Chi, Benjamin Nacev, Jason E. Chan, Emily K. Slotkin, Hannah Kiesler, Travis Adamson, Lilan Ling, Pavitra Rao, Shreyaskumar Patel, Jonathan A. Livingston, Samuel Singer, Narasimhan P. Agaram, Cristina R. Antonescu, Andrew Koff, Joseph P. Erinjeri, Sinchun Hwang, Li-Xuan Qin, Mark T. A. Donoghue, William D. Tap
Summary: This study investigates the efficacy and safety of bempegaldesleukin in combination with nivolumab for refractory sarcoma, and explores potential predictive biomarkers. The results demonstrate higher response rates in specific subtypes of sarcoma, with correlation to CD8+ T cell infiltrates and PD-1 expression. Additionally, upregulation of immune-related pathways and Hedgehog signaling are associated with improved efficacy and resistance, respectively. Further research is needed to assess the effectiveness of this combination therapy in larger patient cohorts and explore the potential of Hedgehog signaling as a predictive biomarker.
NATURE COMMUNICATIONS
(2022)
Review
Medicine, General & Internal
Conor M. Prendergast, Kathleen M. Capaccione, Egesta Lopci, Jeeban P. Das, Alexander N. Shoushtari, Randy Yeh, Daniel Amin, Laurent Dercle, Dorine De Jong
Summary: Advanced melanoma is a deadly cancer with invasive properties and resistance to therapy. Surgery is not always an option for advanced-stage melanoma, and chemotherapy has a poor prognosis. CAR T-cell therapy, successful in hematological cancers, is being tested for advanced melanoma. Radiology, including imaging techniques and PET tracers, will be crucial for monitoring CAR T-cells and therapy response.
Article
Oncology
Karen Kelly, Juliane Manitz, Manish R. Patel, Sandra P. D'Angelo, Andrea B. Apolo, Arun Rajan, Vijay Kasturi, Isabell Speit, Marcis Bajars, John Warth, James L. Gulley
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2020)